Mesoblast Limited

About Mesoblast Limited

Mesoblast is a biotechnology company that utilizes its proprietary mesenchymal lineage cell technology platform to develop and commercialize innovative allogeneic cellular medicines for treating complex inflammatory diseases resistant to conventional standard of care.

Products & Services

RYONCIL:An FDA-approved mesenchymal stromal cell therapy for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGvHD) in pediatric patients 2 months of age and older.

Remestemcel-L:A Phase 3 product candidate for steroid-refractory acute graft versus host disease (acute GVHD) in children and for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection.

REVASCOR®:A Phase 3 product candidate for advanced chronic heart failure.

MPC-06-ID:A Phase 3 product candidate for chronic low back pain due to degenerative disc disease.

Specialties

Mesenchymal lineage cell technology Allogeneic cellular medicines Treatment of inflammatory diseases Cardiovascular diseases Spine orthopedic disorders Oncology hematology Immune-mediated and inflammatory conditions

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Debt T: - FT: Debt	A: 125000000 MR: - FA: US$125 million FAN: 125000000	D: 2025-12-29 FD: 2025-12-29	1 investors
2	RT: Convertible Notes T: - FT: Convertible Notes	A: 50000000 MR: - FA: US$50 million FAN: 50000000	D: 2025-09-03 FD: 2025-09-03	2 investors
3	RT: Convertible Notes T: - FT: Convertible Notes	A: 50000000 MR: - FA: US$50 million FAN: 50000000	D: 2024-09-29 FD: 2024-09-29	1 investors
4	RT: Equity Offering T: - FT: Equity Offering	A: 64020000 MR: - FA: A$97 million FAN: 64020000	D: 2024-03-13 FD: 2024-03-13	2 investors
5	RT: Private Placement T: - FT: Private Placement	A: 40000000 MR: - FA: approximately US$40 million FAN: 40000000	D: 2023-04-25 FD: 2023-04-25	1 investors

Debt Latest

2025-12-29

$125.0M

1 investor (Pro only)

Convertible Notes 2025-09-03

$50.0M

Convertible Notes 2024-09-29

$50.0M

View 4 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Silviu Itescu

Chief Executive Officer (Executive Director)

A

Andrew Chaponnel

Interim Chief Financial Officer

E

Eric Rose

Chief Medical Officer (Executive Director)

D

Dagmar Rosa-Bjorkeson

Chief Operating Officer

R

Roger D. Brown

Spinal Orthopedic Disorders

J

Justin Horst

Deputy Head of Manufacturing

View 15 more team members with Pro

Unlock Full Team Directory

Recent News